HCA Healthcare (NYSE:HCA) PT Raised to $359.00 at Deutsche Bank Aktiengesellschaft

HCA Healthcare (NYSE:HCA) had its price objective boosted by stock analysts at Deutsche Bank Aktiengesellschaft from $330.00 to $359.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 11.21% from the stock’s current price.

A number of other research analysts have also recently commented on the company. Oppenheimer restated an “outperform” rating and issued a $315.00 price target on shares of HCA Healthcare in a research report on Wednesday, January 17th. Truist Financial lifted their target price on HCA Healthcare from $320.00 to $345.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $335.00 target price on shares of HCA Healthcare in a research report on Wednesday. Sanford C. Bernstein cut HCA Healthcare from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $277.00 to $301.00 in a research report on Thursday, January 4th. Finally, Wells Fargo & Company lifted their target price on HCA Healthcare from $303.00 to $315.00 and gave the company an “equal weight” rating in a research report on Thursday, March 28th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, HCA Healthcare has an average rating of “Moderate Buy” and a consensus target price of $314.05.

HCA Healthcare Stock Down 1.4 %

HCA opened at $322.82 on Friday. HCA Healthcare has a fifty-two week low of $215.96 and a fifty-two week high of $335.83. The company has a debt-to-equity ratio of 35.07, a quick ratio of 1.02 and a current ratio of 1.18. The company has a market capitalization of $85.38 billion, a P/E ratio of 17.01, a P/E/G ratio of 1.64 and a beta of 1.65. The stock has a fifty day moving average of $319.77 and a 200-day moving average of $279.40.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Tuesday, January 30th. The company reported $5.90 earnings per share for the quarter, topping analysts’ consensus estimates of $5.05 by $0.85. HCA Healthcare had a return on equity of 996.30% and a net margin of 8.07%. The company had revenue of $17.30 billion during the quarter, compared to the consensus estimate of $16.51 billion. During the same quarter last year, the firm earned $4.64 earnings per share. The company’s revenue was up 11.7% on a year-over-year basis. On average, equities analysts expect that HCA Healthcare will post 20.49 EPS for the current year.

HCA Healthcare declared that its Board of Directors has initiated a stock buyback plan on Tuesday, January 30th that allows the company to repurchase $6.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 7.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,200 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $306.79, for a total transaction of $981,728.00. Following the completion of the sale, the executive vice president now owns 24,929 shares in the company, valued at $7,647,967.91. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Kathryn A. Torres sold 3,861 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $307.00, for a total transaction of $1,185,327.00. Following the completion of the sale, the senior vice president now owns 15,899 shares in the company, valued at $4,880,993. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael S. Cuffe sold 3,200 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $306.79, for a total value of $981,728.00. Following the sale, the executive vice president now owns 24,929 shares of the company’s stock, valued at approximately $7,647,967.91. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,840 shares of company stock valued at $4,588,869. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On HCA Healthcare

Institutional investors have recently bought and sold shares of the stock. abrdn plc grew its holdings in HCA Healthcare by 4.8% during the third quarter. abrdn plc now owns 164,419 shares of the company’s stock worth $40,444,000 after buying an additional 7,476 shares in the last quarter. Soros Fund Management LLC bought a new position in HCA Healthcare in the 3rd quarter valued at $10,085,000. DNB Asset Management AS grew its stake in HCA Healthcare by 14.1% in the 4th quarter. DNB Asset Management AS now owns 60,682 shares of the company’s stock valued at $16,425,000 after purchasing an additional 7,476 shares during the period. Comerica Bank grew its stake in HCA Healthcare by 623.3% in the 3rd quarter. Comerica Bank now owns 43,502 shares of the company’s stock valued at $10,701,000 after purchasing an additional 37,488 shares during the period. Finally, Handelsinvest Investeringsforvaltning bought a new position in HCA Healthcare in the 4th quarter valued at $1,100,000. Institutional investors own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.